Combining Single-walled Carbon Nanotubes With Anticancer Agents”SN-38” and EGFR antibody for Colorectal Cancer Targeting Chemotherapeutics

• Main Authors: Yu-Chi Chiou, 邱鈺棋
• Other Authors: Shieh Ming-Jium
• Format: Others
• Language: en_US
• Published: 2012
• Online Access: http://ndltd.ncl.edu.tw/handle/68157034904445828468

碩士 === 國立臺灣大學 === 醫學工程學研究所 === 100 === Single-walled carbon nanotubes (SWNTs) combined with chemotherapeutic drug 7-Ethyl-10-hydroxy-camptothecin (SN-38) and monoclonal antibody Erbitux (C225) . The carriers were designed to explore the specific binding ability, anti-proliferation ability against to colorectal cancer cell lines and drug control release. The monoclonal antibody Erbitux (C225) bind to EGFR specifically. Therefore the subjects here were 3 kinds of colorectal cancer cell lines with different level of EGFR expression. EGFR expression level of these cells is: HCT116>HT29>SW620. SWNT25/pyCPY carrier reduce more than 50% cellular viability to all these 3 kinds of cells. Moreover the cell viability of EGFR over-expressing cell HCT116 is only 10%. The cellular viability is lower while the cell’s EGFR expression is higher. The anti-proliferation ability of SWNT25/py38 carrier is EGFR-depending and EGFR-Targeting. The drug control release process was designed to utilizing Human Carboxylesterase enzyme (hCE) to detach the SN-38 from SWNTs .This drug-release process is supposed by hCE would broke the ester bond link the SN-38 and Pyrene. The percentage of SN38 releasing from SWNTs carrier in physical environment pH7.4 buffer(20%) is much lower than cell lysate(60%) and hCE(80%). The SWNT25/py38 carrier using C225 specifically bind to EGFR expressing cell and releasing abundant SN38 to kill the cells.